2,118 reports of this reaction
4.5% of all IMATINIB MESYLATE reports
#2 most reported adverse reaction
NAUSEA is the #2 most commonly reported adverse reaction for IMATINIB MESYLATE, manufactured by Novartis Pharmaceuticals Corporation. There are 2,118 FDA adverse event reports linking IMATINIB MESYLATE to NAUSEA. This represents approximately 4.5% of all 47,520 adverse event reports for this drug.
Patients taking IMATINIB MESYLATE who experience nausea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NAUSEA is moderately reported among IMATINIB MESYLATE users, representing a notable but not dominant share of adverse events.
In addition to nausea, the following adverse reactions have been reported for IMATINIB MESYLATE:
The following drugs have also been linked to nausea in FDA adverse event reports:
NAUSEA has been reported as an adverse event in 2,118 FDA reports for IMATINIB MESYLATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
NAUSEA accounts for approximately 4.5% of all adverse event reports for IMATINIB MESYLATE, making it one of the most commonly reported side effect.
If you experience nausea while taking IMATINIB MESYLATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.